VRTX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Vertex Pharmaceuticals Incorporated investment
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals' SWOT analysis: stock outlook amid pipeline progress
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
Yahoo Finance27d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...
Benzinga.com1mon
Check Out What Whales Are Doing With VRTX
Anticipated earnings release is in 47 days ... Stay informed about the latest Vertex Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
Yahoo Finance28d
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): ‘This Is Hardly Down For The Year. I Think It Can Still Go Lower’
In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... the Personal Consumption Expenditure (PCE) data release. The PCE data was a boon for investors ...
Nasdaq1mon
Vertex Pharmaceuticals price target lowered to $522 from $545 at BofA
BofA lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $522 from $545 and keeps a Buy rating on the shares after the company reported topline Phase 2 results for suzetrigine in ...
Business Wire1mon
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P ...